About Bio-Techne Corp (TECH)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applica

TECH Key Statistics

TECH Price Performance

Bio-Techne Corp stock has returned -3.39% over the past day, -3.50% over the past week, -6.13% over the past month, and -15.78% over the past three months. The stock trades between a 52-week low of $46.01 and a high of $72.16.

TECH Financial Fundamentals

Bio-Techne Corp reports a return on equity (ROE) of +3.96%, operating margin of +22.60%, profit margin of +666.90%, and revenue growth of +164.00%. The debt-to-equity ratio is 0.17. Current ratio stands at 4.54.

TECH Earnings

Bio-Techne Corp's next earnings report is expected on 2026-05-06 (62 days away). The company has a +0.75% earnings beat rate with an average surprise of +3.36%. Earnings consistency is rated as "high".

TECH Ownership

Institutional investors hold approximately +1.14% of TECH shares across 10 institutions. Insider ownership is +0.00%. Insider sentiment is "bearish".

TECH Short Interest

TECH has a short interest of +8.24% of float with a short ratio (days to cover) of 4.2.

TECH AI Analysis Signal

iGotFomo's AI-powered signal engine rates TECH as "LEAN SELL" with LOW confidence (score: 31/100). 4 signals are bullish, 6 are bearish, and 2 are neutral.